نتایج جستجو برای: dexrazoxane

تعداد نتایج: 227  

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2002
Patricia E Schroeder Jeffrey N Davidson Brian B Hasinoff

The enzyme kinetics of the hydrolysis of the one-ring open metabolites of the antioxidant cardioprotective agent dexrazoxane [ICRF-187; (+)-1,2-bis(3,5-dioxopiperazin-1-yl)propane] to its active metal ion binding form ADR-925 [N,N'-[(1S)-1-methyl-1,2-ethanediyl]bis[N-(2-amino-2-oxoethyl)glycine] by dihydroorotase (DHOase) has been investigated by high-performance liquid chromatography (HPLC). A...

2016
Pranitha Kamat Stijn Vandenberghe Stephan Christen Anjan K. Bongoni Bernhard Meier Robert Rieben Ahmed A. Khattab

Calcium and iron overload participate in the mechanisms of ischemia/reperfusion (I/R) injury during myocardial infarction (MI). Calcium overload induces cardiomyocyte death by hypercontraction, while iron catalyses generation of reactive oxygen species (ROS). We therefore hypothesized that dexrazoxane, an intracellular metal chelator, would attenuate I/R injury. MI was induced in pigs by occlus...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2007
H T Mouridsen S W Langer J Buter H Eidtmann G Rosti M de Wit P Knoblauch A Rasmussen K Dahlstrøm P B Jensen G Giaccone

BACKGROUND The purpose of this study was to assess the efficacy and tolerability of i.v. dexrazoxane [Savene (EU), Totect (US)] as acute antidote in biopsy-verified anthracycline extravasation. PATIENTS AND METHODS Two prospective, open-label, single-arm, multicentre studies in patients with anthracycline extravasation were carried out. Patients with fluorescence-positive tissue biopsies were...

Journal: :Onkologie 2008
Lisa Schulmeister

treatment of an intrathoracic epirubicin extravasation [3]. Approximately 140 mg of epirubicin extravasated into the pleural space when the tip of an implanted port catheter became misplaced. A pleural drain was inserted and the pleural cavity was immediately flushed with 1000 ml normal saline on 2 consecutive days. Dexrazoxane was also infused intravenously for the first three consecutive days...

Journal: :Arquivos brasileiros de cardiologia 2006
Ranulfo Pinheiro de Matos Neto Antônio Sérgio Petrilli Célia Maria Campos Silva Orlando Campos Filho Victor Manuel Oporto Lourdes de Fátima Gonçalves Gomes Marcelo Goulart Paiva Antônio Carlos Camargo Carvalho Valdir Ambrósio Moisés

OBJECTIVE To evaluate left ventricular (LV) systolic function by means of echocardiography in patients with osteosarcoma treated with doxorubicin alone or in combination with dexrazoxane. METHODS The study analyzed 55 patients with osteosarcoma, with or without metastasis, undergoing a six-cycle chemotherapy regimen of doxorubicin, who were divided into two groups according to dexrazoxane use...

Journal: :World journal of clinical oncology 2016
Firas Y Kreidieh Hiba A Moukadem Nagi S El Saghir

Chemotherapy extravasation remains an accidental complication of chemotherapy administration and may result in serious damage to patients. We review in this article the clinical aspects of chemotherapy extravasation and latest advances in definitions, classification, prevention, management and guidelines. We review the grading of extravasation and tissue damage according to various chemotherape...

Journal: :Anticancer research 2016
Tim A D Smith Su M Phyu Emmanuel U Akabuogu

BACKGROUND Anticancer drug treatment, particularly with anthracyclines, is frequently associated with cardiotoxicity, an effect exacerbated by trastuzumab. Several compounds are in use clinically to attenuate the cardiac-damaging effects of chemotherapy drugs, including angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, the anti-diabetic drug metformin, and dexrazoxane. However, the...

Journal: :Biomedicine & Pharmacotherapy 2021

Cancer is one of the leading causes deaths worldwide with 18.1 million per year. Although there have been significant advances in anti-cancer therapies, they can often result side effects cardiovascular complications being most severe. Dexrazoxane only currently approved treatment for prevention anthracycline induced cardiotoxicity but are concerns about its use due to development secondary mal...

Journal: :Journal of Medicinal Chemistry 2021

Cardioprotective activity of dexrazoxane (ICRF-187), the only clinically approved drug against anthracycline-induced cardiotoxicity, has traditionally been attributed to its iron-chelating metabolite. However, recent experimental evidence suggested that inhibition and/or depletion topoisomerase II? (TOP2B) by could be cardioprotective. Hence, we evaluated a series analogues and found their card...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید